These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 30319638)
21. Tumor cells express and maintain HMGB1 in the reduced isoform to enhance CXCR4-mediated migration. Pirani E; Paparoditis P; Pecoraro M; Danelon G; Thelen M; Cecchinato V; Uguccioni M Front Immunol; 2024; 15():1358800. PubMed ID: 38803493 [TBL] [Abstract][Full Text] [Related]
22. Systematic Development of Peptide Inhibitors Targeting the CXCL12/HMGB1 Interaction. Sgrignani J; Cecchinato V; Fassi EMA; D'Agostino G; Garofalo M; Danelon G; Pedotti M; Simonelli L; Varani L; Grazioso G; Uguccioni M; Cavalli A J Med Chem; 2021 Sep; 64(18):13439-13450. PubMed ID: 34510899 [TBL] [Abstract][Full Text] [Related]
23. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases. Liepelt A; Tacke F Am J Physiol Gastrointest Liver Physiol; 2016 Aug; 311(2):G203-9. PubMed ID: 27313175 [TBL] [Abstract][Full Text] [Related]
24. The good and bad faces of the CXCR4 chemokine receptor. Teixidó J; Martínez-Moreno M; Díaz-Martínez M; Sevilla-Movilla S Int J Biochem Cell Biol; 2018 Feb; 95():121-131. PubMed ID: 29288743 [TBL] [Abstract][Full Text] [Related]
25. Human Cytomegalovirus UL111A and US27 Gene Products Enhance the CXCL12/CXCR4 Signaling Axis via Distinct Mechanisms. Tu CC; Arnolds KL; O'Connor CM; Spencer JV J Virol; 2018 Mar; 92(5):. PubMed ID: 29237840 [TBL] [Abstract][Full Text] [Related]
26. Non-oxidizable HMGB1 induces cardiac fibroblasts migration via CXCR4 in a CXCL12-independent manner and worsens tissue remodeling after myocardial infarction. Di Maggio S; Milano G; De Marchis F; D'Ambrosio A; Bertolotti M; Palacios BS; Badi I; Sommariva E; Pompilio G; Capogrossi MC; Raucci A Biochim Biophys Acta Mol Basis Dis; 2017 Nov; 1863(11):2693-2704. PubMed ID: 28716707 [TBL] [Abstract][Full Text] [Related]
27. Natural nitration of CXCL12 reduces its signaling capacity and chemotactic activity in vitro and abrogates intra-articular lymphocyte recruitment in vivo. Janssens R; Mortier A; Boff D; Vanheule V; Gouwy M; Franck C; Larsen O; Rosenkilde MM; Van Damme J; Amaral FA; Teixeira MM; Struyf S; Proost P Oncotarget; 2016 Sep; 7(38):62439-62459. PubMed ID: 27566567 [TBL] [Abstract][Full Text] [Related]
28. Chemokines in cancer. Chow MT; Luster AD Cancer Immunol Res; 2014 Dec; 2(12):1125-31. PubMed ID: 25480554 [TBL] [Abstract][Full Text] [Related]
29. Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events. Gouwy M; Struyf S; Noppen S; Schutyser E; Springael JY; Parmentier M; Proost P; Van Damme J Mol Pharmacol; 2008 Aug; 74(2):485-95. PubMed ID: 18469140 [TBL] [Abstract][Full Text] [Related]
30. Diflunisal targets the HMGB1/CXCL12 heterocomplex and blocks immune cell recruitment. De Leo F; Quilici G; Tirone M; De Marchis F; Mannella V; Zucchelli C; Preti A; Gori A; Casalgrandi M; Mezzapelle R; Bianchi ME; Musco G EMBO Rep; 2019 Oct; 20(10):e47788. PubMed ID: 31418171 [TBL] [Abstract][Full Text] [Related]
31. Inflammatory chemokines and metastasis--tracing the accessory. Borsig L; Wolf MJ; Roblek M; Lorentzen A; Heikenwalder M Oncogene; 2014 Jun; 33(25):3217-24. PubMed ID: 23851506 [TBL] [Abstract][Full Text] [Related]
32. An infernal trio: the chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology. Hattermann K; Mentlein R Ann Anat; 2013 Mar; 195(2):103-10. PubMed ID: 23279723 [TBL] [Abstract][Full Text] [Related]
33. Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins. Nasser MW; Elbaz M; Ahirwar DK; Ganju RK Cancer Lett; 2015 Aug; 365(1):11-22. PubMed ID: 25963887 [TBL] [Abstract][Full Text] [Related]
34. The acidic intrinsically disordered region of the inflammatory mediator HMGB1 mediates fuzzy interactions with CXCL12. Mantonico MV; De Leo F; Quilici G; Colley LS; De Marchis F; Crippa M; Mezzapelle R; Schulte T; Zucchelli C; Pastorello C; Carmeno C; Caprioglio F; Ricagno S; Giachin G; Ghitti M; Bianchi ME; Musco G Nat Commun; 2024 Feb; 15(1):1201. PubMed ID: 38331917 [TBL] [Abstract][Full Text] [Related]
35. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nagarsheth N; Wicha MS; Zou W Nat Rev Immunol; 2017 Sep; 17(9):559-572. PubMed ID: 28555670 [TBL] [Abstract][Full Text] [Related]
36. CCL7 Signaling in the Tumor Microenvironment. Lee YS; Cho YB Adv Exp Med Biol; 2020; 1231():33-43. PubMed ID: 32060844 [TBL] [Abstract][Full Text] [Related]
38. MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling. Klasen C; Ohl K; Sternkopf M; Shachar I; Schmitz C; Heussen N; Hobeika E; Levit-Zerdoun E; Tenbrock K; Reth M; Bernhagen J; El Bounkari O J Immunol; 2014 Jun; 192(11):5273-84. PubMed ID: 24760155 [TBL] [Abstract][Full Text] [Related]
39. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? Hirbe AC; Morgan EA; Weilbaecher KN Curr Pharm Des; 2010; 16(11):1284-90. PubMed ID: 20166978 [TBL] [Abstract][Full Text] [Related]
40. The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment. Susek KH; Karvouni M; Alici E; Lundqvist A Front Immunol; 2018; 9():2159. PubMed ID: 30319622 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]